Vignesh Gopinath,
- Student, Department of Bioinformatics, Bangalore City University, Bengaluru, Karnataka,
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_114131’);});Edit Abstract & Keyword
Objectives: Triple Negative Breast Cancer (TNBC) is a very dangerous form of cancer which affects mostly Hispanic and African American women above the age of 40. It represents approximately 15-20% of the global cancer incidence. This experiment aims to investigate the use of Gingko biloba in the treatment of the disease Triple negative Breast cancer (TNBC). Methods: We use a variety of online tools, and websites, including the IMPPAT database, to extract the phytochemical compounds, the PubChem website to obtain the canonical SMILES , and the 2-d format is used to download the SDF files, the PDB Website to download the protein files in PDB format, the Ramachandran’s Plot. This way , we can visualize that in the Discovery Studio BIOVIA App. Then, the Swiss ADME website is used to find which compounds satisfy Lipinski’s rule, and the other conditions. Result: The results showed that the compounds Afzelin, D-Glucuronic acid, Gingketin, Acacetin, Quercetin, Isoginkgetin, Genkwanin satisfy all the criteria, and could be further used in the treatment of TNBC. Conclusion: The observations suggest that the below mentioned phytochemical compounds – Afzelin, D – Glucuronic acid, Gingketin, Acacetin, Quercetin, Isoginkgetin, and Genkwanin seem to satisfy all the conditions for it to be used in the ADME testing and analysis and can be used in treatment of TNBC.
Keywords: Triple Negative Breast Cancer (TNBC), Breast Cancer Gene-1 (BRCA), CK2 alpha kinase.
[This article belongs to International Journal of Bioinformatics and Computational Biology (ijbcb)]
Vignesh Gopinath. Exploring the Role of Ginkgo biloba in Investigating 7L1X in Triple-Negative Breast Cancer through Integrative Bioinformatics. International Journal of Bioinformatics and Computational Biology. 2024; 02(02):-.
Vignesh Gopinath. Exploring the Role of Ginkgo biloba in Investigating 7L1X in Triple-Negative Breast Cancer through Integrative Bioinformatics. International Journal of Bioinformatics and Computational Biology. 2024; 02(02):-. Available from: https://journals.stmjournals.com/ijbcb/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_114131’);});Edit
1. .Aysola K, Desai A, Welch C, Xu J, Qin Y, Reddy V, Matthews R, Owens C, Okoli J, Beech DJ, Piyathilake CJ. Triple negative breast cancer–an overview. Hereditary genetics: current research. 2013 Jan 1;2013(Suppl 2). 2. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast cancer research and treatment. 2011 Feb;125:627-36. 3. Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World journal of clinical oncology. 2014 May 5;5(2):125. 4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nature reviews Clinical oncology. 2010 Dec;7(12):683-92. 5. Sharma P. Biology and management of patients with triple-negative breast cancer. The oncologist. 2016 Sep 1;21(9):1050-62. 6. Jia LY, Shanmugam MK, Sethi G, Bishayee A. Potential role of targeted therapies in the treatment of triple-negative breast cancer. Anti-Cancer Drugs. 2016 Mar 1;27(3):147-55. 7. Guney Eskiler G, Cecener G, Egeli U, Tunca B. Triple negative breast cancer: new therapeutic approaches and BRCA status. Apmis. 2018 May;126(5):371-9. 8. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. The lancet oncology. 2007 Mar 1;8(3):235-44. 9. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clinical oncology. 2011 Nov 1;23(9):587-600. 10. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nature reviews Clinical oncology. 2016 Nov;13(11):674-90. 11. Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy. Breast cancer research. 2015 Dec;17:1-21. 12. Morelos-Garnica LA, Guzmán-Velázquez S, Padilla-Martínez II, García-Sánchez JR, Bello M, Bakalara N, Méndez-Luna D, Correa-Basurto J. In silico design and cell-based evaluation of two dual anti breast cancer compounds targeting Bcl-2 and GPER. Scientific Reports. 2023 Oct 20;13(1):17933. 13. Chen, X., Wu, Q., & Tan, L. (2020). The potential anticancer effect of Ginkgo biloba extract: A review of the literature. Journal of Cancer Research and Therapeutics, 16(5), 987-993. doi:10.4103/jcrt.JCRT_342_19. 14. Kim, H. J., Lee, J. W., & Kim, D. I. (2022). Molecular and bioinformatics approaches in exploring the therapeutic potential of Ginkgo biloba in breast cancer. Phytomedicine, 100, 154059. doi:10.1016/j.phymed.2021.154059. 15. Shoaib TH, Ibraheem W, Abdelrahman M, Osman W, Sherif AE, Ashour A, Ibrahim SR, Ghazawi KF, Miski SF, Almadani SA, ALsiyud DF. Exploring the potential of approved drugs for triple-negative breast cancer treatment by targeting casein kinase 2: Insights from computational studies. PLoS One. 2023 Aug 14;18(8):e0289887. 16. Anderson RJ, Weng Z, Campbell RK, Jiang X. Main‐chain conformational tendencies of amino acids. Proteins: Structure, Function, and Bioinformatics. 2005 Sep 1;60(4):679-89. 17. Gopalakrishnan K, Sowmiya G, Sheik SS, Sekar K. Ramachandran plot on the web (2.0). Protein and peptide letters. 2007 Jul 1;14(7):669-71. 18. Almansour NM. Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence. Frontiers in Molecular Biosciences. 2022 Jan 25;9:836417. 19. Ho BK, Brasseur R. The Ramachandran plots of glycine and pre-proline. BMC structural biology. 2005 Dec;5:1-1.
| Volume | 02 |
| Issue | 02 |
| Received | 02/06/2024 |
| Accepted | 12/11/2024 |
| Published | 18/11/2024 |